“…6,24 Strongly driven by the potential to treat cancer with Hsp90 inhibitors, the development of such inhibitors has rapidly progressed in the last years and there currently exists a broad range of pharmacophores ranging from natural ansamycins to synthetic derivatives of purine, resorcinol, benzamide, aminopyri(mi)dines, and tricyclic imidazopyridines. 9,25,26 In contrast, the development of species-specific Hsp90 inhibitors is still in its infancy. We previously presented a living test system based on the growth of a panel of isogenic yeast strains, each living on Hsp90 from a different species.…”